Dr. Claire de la Calle

PSA density is, I think, a very important biomarker.

Going back to just PSA, PSA is actually the only biomarker that's really approved by guidelines for active surveillance monitoring.

And PSA density is an important factor in many, many studies, active surveillance studies.

It's been associated with progression of

On surveillance, usually the cutoff of 0.15 is used, but other cutoffs have been studied as well.

In grade group 2 patients specifically, studies have shown that those patients, if they have a high PSA density, they're more likely to have adverse pathology at radical prostatectomy.

So I definitely take into account.

PSA density when counseling patients.

Now, I don't necessarily use it as a complete exclusion criteria.

I'm sure we all have a few patients with high PSA density, but I will definitely wonder, is there more volume of tumor that's not really well sampled?

So do I need to repeat an early biopsy?

I will monitor them more closely.

Hi, thank you so much for having me.

I am an assistant professor at the University of Washington and Fred Hutch Cancer Center.

My practice is mostly prostate cancer and some bladder cancer as well.

I dedicate 50% of my time to research and all of my research is around active surveillance.

I'm highly interested in working on biomarkers to better identify patients that are good candidates versus not good candidates for active surveillance.

And this is a very important topic for intermediate risk patients on active surveillance.

So I'm really excited about the conversation we're going to have today.

Yeah, definitely.